TUCSON, Ariz.--(BUSINESS WIRE)--Ventana Medical Systems, Inc. (NASDAQ: VMSI), the global leader in tissue-based cancer diagnostics, today announced that due to the expected positive financial impact of the Company’s acquisition of Spring BioScience Corporation, an industry-leading developer and supplier of next generation rabbit monoclonal antibodies and other reagents, Ventana has revised its outlook for 2008 and 2009.
